Narrow-leafed lupin (Lupinus angustifolius L.) beta-conglutin proteins modulate the insulin signaling pathway as potential type 2 diabetes treatment and inflammatory-related disease amelioration
Elena Lima-Cabello, Victor Alche, Rhonda C Foley, Sofianos Andrikopoulos, Grant Morahan, Karam B Singh, Juan D Alche, Jose C Jimenez-Lopez
MOLECULAR NUTRITION & FOOD RESEARCH | WILEY | Published : 2017
SCOPE: We have investigated the potential use of β-conglutin protein isoforms from narrow-leafed lupin (Lupinus angustifolius L.) as a diabetes treatment. METHODS AND RESULTS: We produced purified recombinant β1-, β2-, β3-, β4-, and β6-conglutin proteins and showed that β1, β3, and β6 could bind to insulin. To assess β-conglutin proteins modulatory effect on insulin activation meditated kinases, whole blood and peripheral blood mononuclear cell cultures from type 2 diabetes (T2D) and healthy control subjects (C) were incubated with conglutin proteins. The treatment of peripheral blood mononuclear cells from T2D patients with β1, β3, and β6 proteins increased up to threefold mRNA and protein ..View full abstract
Awarded by European Research Program MARIE CURIE (FP7-PEOPLE-2011-IOF)
Awarded by Spanish Ministry of Economy and Competitiveness
This study has been funded by the European Research Program MARIE CURIE (FP7-PEOPLE-2011-IOF) under the grant ref. number PIOF-GA-2011-301550 to J.C.J.-L., K.B.S., and J.D.A.; J.C.J.-L. thanks the Spanish Ministry of Economy and Competitiveness for the grant ref. number RYC-2014-16536 (Ramon y Cajal Research Program).